http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-054615-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D221-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| filingDate | 2006-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec5259d4bcf1ec96d6d484b498b95254 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7f5f50361f2be0b5ca3a1d2ed9dca33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_feb29b1d69ea0d4b4344c137083a4bf4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d630df8e0978f99858e02c7a12f6d25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1eac882e27f0f0e850ad2d25aecd8421 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19fc0a8a394a71196adf36d1972b3e6c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06804fb2083df0d0be05a0d467c109ae |
| publicationDate | 2007-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-054615-A1 |
| titleOfInvention | TETRAHYDROQUINOLINS |
| abstract | Compounds of formula (1), where: W is CH or N; R 1, R2, R3 independently of each other, H, A, aryl, heteroaryl, Hal, - (CY2) n-SA, - (CY2) n-SCF3, - (CY2) n-SCN, - (CY2) n- CF3, - (CY2) n-OCF3, cycloalkyl, -SCH3, -SCN, -CF3, -OCF3, -OA, - (CY2) n-OH, - (CY2) n- CO2R, - (CY2) n-Hal , - (CH2) nR, - (CY2) n-NR2, - (CY2) n-OR, - (CY2) n-OCOA, -SCF3, - (CY2) n-CONR2, - (CY2) n-NHCOA, - (CY2) n-NHSO2A, SF5, Si (CH3) 3, CO- (CY2) n-CH3, - (CY2) nN-pyrrolidone, - (CH2) nNRCOOR, NRCOOR, NCO, CH2 (CH2) nCOOR, NHCOOR , CH2- (CH2) n-OH, - NR (CH2) nOH, CH2NH2, (CH2) nNR2, CH (OH) R2, CH2NHCOR, (CH2) naryl, CH2 (CH2) nheteroaryl, (CH2) nR1, NH ( CH2) nCOOR, CH2 (CH2) nX (CH2) naryl, (CH2) (CH2) nX (CH2) nheteroaryl, NH (CH2) nCONR2, XCONR (CH2) nNR2, N [(CH2) nXCOOR] CO (CH2) naryl , N [(CH2) nXR] CO (CH2) naryl, N [(CH2) nXR] CO (CH2) nX-aryl, N [(CH2) nXR] SO2 (CH2) naryl, N [(CH2) nNRCOOR] CO (CH2) Naryl, N [(CH2) nNR2] CO (CH2) Naryl, N [(CH2) nNR2] CO (CH2) nNR-aryl, N [(CH2) nNR2] SO2 (CH2) Naryl, N [(CH2 ) nXR] CO (CH2) nheteroaryl, N [(CH2) nXR] CO (CH2) nX-heteroaryl, N [(CH2) nXR] SO2 (CH2) nheteroaryl, N [(CH2) nNRCOOR] CO (CH2) nheteroaryl , N [(CH2) nNR2] CO (CH2) nheteroaryl, N [(CH2) nNR2] CO (CH2) nNR-heteroaryl, where non-neighboring CY2 groups can also be replaced by X, R1, and R3 together can also mean - NC (CF3) = N-, -N-CR = N-, -NN = N-; Y is H, A, Hal, OR1, N (R1) 2, E-R1; A is alkyl or cycloalkyl, where one or more H atoms may be replaced by Hal and / or one or more non-neighboring CH2 groups may be replaced by X; Hal is F, Cl, Br or I; R is H or A, in geminal residues together also - (CH2) 5-, - (CH2) 4-, or - (CH2) n-X- (CH2) n, or - (CH2) n-Z- (CH2) n; R4 is H; R5 is independently from each other, H or N-pyrrolidone unsubstituted or substituted once or several times with OR, NO2, Hal, CF3, OCF3, CN, NR2, or SR, aryl or heteroaryl, -X- (CH2) 2OR, - X-CO (CH2) nCH3, -X- (CH2) 2NR2, R1, S-aryl, O-aryl, CH2Si (CH3) 3, Q, - (CY2) nE-CR2R1, - (CY2) nE-CR2XR1, - (CY2) nE- (CY2) n-XR1 or - (CY2) nE- (CY2) n-XRa; E is -NR1SO2-, -SO2NR1-, - CONR1-, NR1CO-, -COO-, -OOC-, -NR1CONR1-, OCONR1-, -NR1COO-, -CSNR1-, -NR1CS-, -NR1CSNR1-, -SCONR1 -, -NR1COS_, -OCSNR1-, -NR1CSO-, -SCSNR1-, -NR1CSS- or a simple ligature; X is O, S, or NR1; Q is (CH2) pHal, CHO, CORa, (CH2) pRa, (CH2) pOCORa, (CH2) pXR1, (CH2) pNCOR1, (CH2) pN (R1) 2, (CH2) pOR1, (CH2) pOCON ( R1) 2, (CH2) pOCOOR1, (CH2) pNHCON (R1) 2, (CH2) pNHCOOR1, (CH2) pCN, (CH2) pCOOR1, (CH2) pE- (CH2) pR1, (CH2) pE- (CH2 ) pRa, where non-neighboring CH2 groups may also be replaced by X; or is a remainder selected from the group of formulas (2); or is OR, NHR, NR2, NR (CH2) naryl, NR (CH2) nOR, COOR, N-pyrrolidone residue, OCOR, NR (CH2) nR2, N [(CH2) nNR2] CO (CH2) naryl, N [(CH2) nNHCOOR] CO-aryl, R1, N [CH2 (CH2) nOR] 2, NR (CH2) nNCOOR, X (CH2) nX (CH2) nXR, NR (CH2) nX (CH2) nOH, NR ( CH2) nO (CH2) nOH, (CH2) nCOOR, O (CO) NR (CH2) nOR, O (CO) (CH2) nNR2, NR (CH2) nNR2, N [(CH2) nNR2] CO (CH2) naryl , N [(CH2) nXR] CO (CH2) naryl, N [(CH2) nXR] CO (CH2) nheteroaryl, N [(CH2) nNR2] CO (CH2) nheteroaryl, N [(CH2) nNR2] CO (CH2 ) nR1, N (R) (CH2) nN (R) COOR, XCOO (CH2) nNR2, OSO2A, OSO2CF3, OSO2Ar, OCONR2, OCH2 (CH2) nNR2; Z is CH2, X, CHCONH2, CH (CH2) nNR1COOR1, CHNR1COOR1, CHCON (R1) 2, NCO, CH (CH2) nCOOR1, NCOOR1, CH (CH2) nOH, N (CH2) nOH, CHNH2, CH (CH2) nN (R1) 2, C (OH) R1, CHNCOR1, NCOR1, N (CH2) naryl, N (CH2) nheteroaryl, CHR1, NR1, CH (CH2) naryl, CH (CH2) nheteroaryl, CH (CH2) nR1, N (CH2) nCOOR1, CH (CH2) nX (CH2) nR1, CH (CH2) nX (CH2) nRa, N (CH2) nCON (R1) 2, XCONR1 (CH2) nN (R1) 2, CO (CH2) nR1, CO (CH2) nR1, CO (CH2) nXR1, SO2 (CH2) nR1, O (CH2) nN (R1) 2, X (CH2) nN (R1) 2, NCO (CH2) nN (R1) 2, CHRa, NRa; R6 is aryl or heteroaryl unsubstituted or substituted once or several times by aryl or heteroaryl, which may be substituted by Hal, NO2, CN, A, OR, OCOR, COR, NR2, CF3, OCF3, OCH (CF3) 2, Hal , NO2, CN, OR, - (CY2) n-OR, -OCOR, - (CY2) n-CO2R, - (CY2) n-CN, -NCOR, -COR or - (CY2) n-NR2; R7 is (C = O) -R, (C = O) -NR2, (C = O) -OR, H or A, where R5 and R7 together can also mean - (CH2) n-; m is 0, 1 or 2, n is 0, 1, 2, 3, 4, 5, 6 or 7, and p is 0, 1, 2, 3, 4 or 5, preferably 2 or 3, s is 0, 1 , 2, 3, 4, 5, 6 or 7, preferably 0; as well as its derivatives, solvates, tautomers, pharmaceutically usable salts and stereoisomers, including their mixtures in all proportions. They can be used, among others, for the treatment of tumors. |
| priorityDate | 2005-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 39.